Pharma giant agrees to license new HIV prevention drug to 120 countries
Pharmaceutical giant Gilead Sciences approved new license agreements for lenacapavir an antiretroviral medication which provides near-total protection from HIV infection. The drug, packaged as Sunlenca in the US (sold for $42,250 a year for two injections …